Bambuterol
 |
|
Bambuterol (top),
and (R)-bambuterol (bottom) |
|
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| Pregnancy category |
|
| Routes of administration |
Oral (tablets) |
| ATC code | R03CC12 (WHO) |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 20% |
| Metabolism | Extensive hepatic. Further metabolized to terbutaline by plasma cholinesterase |
| Biological half-life | 13 hours (bambuterol) 21 hours (terbutaline) |
| Excretion | Renal |
| Identifiers | |
|
|
| CAS Number | 81732-46-9  |
| PubChem (CID) | 54766 |
| IUPHAR/BPS | 6601 |
| DrugBank | DB01408  |
| ChemSpider | 49466 |
| UNII | Y1850G1OVC |
| KEGG | D07377 |
| ChEBI | CHEBI:553827 |
| ChEMBL | CHEMBL521589 |
| ECHA InfoCard | 100.171.084 |
| Chemical and physical data | |
| Formula | C18H29N3O5 |
| Molar mass | 367.44 g/mol |
| 3D model (Jmol) | Interactive image |
| Chirality | Racemic mixture |
|
|
|
|
| (what is this?) (verify) |
|
Bambuterol (INN) is a long-acting β adrenoceptor agonist (LABA) used in the treatment of asthma; it also is a prodrug of terbutaline. Commercially, the AstraZeneca pharmaceutical company produces and markets bambuterol as Bambec and Oxeol.[1]
It is not available in the U.S.
Indications[edit]
As other LABAs, bambuterol is used in the long-term management of persistent asthma.[1] It should not be used as a rescue medication for short-term relief of asthma symptoms.
Contraindications[edit]
Bambuterol is contraindicated in pregnancy and in people with seriously impaired liver function. It can be used by people with renal impairment, but dose adjustments are necessary.[1]
Adverse effects[edit]
The adverse effect profile of bambuterol is similar to that of salbutamol, and may include fatigue, nausea, palpitations, headache, dizziness and tremor.[1]
Interactions[edit]
Concomitant administration of bambuterol with corticosteroids, diuretics, and xanthine derivatives (such as theophylline) increases the risk of hypokalemia (decreased levels of potassium in the blood).[2]
Bambuterol acts as a cholinesterase inhibitor, and can prolong the duration of action of suxamethonium (succinylcholine) and other drugs whose breakdown in the body depends on cholinesterase function.[1] Butyrylcholinesterase activity returns to normal approximately two weeks after bambuterol is stopped.[3] It can also enhance the effects of non-depolarizing neuromuscular blockers, such as vecuronium bromide.[2]
References[edit]
- ^ a b c d e Sweetman, Sean C., ed. (2009). "Bronchodilators and Anti-asthma Drugs". Martindale: The complete drug reference (36th ed.). London: Pharmaceutical Press. pp. 1115–16. ISBN 978-0-85369-840-1.
- ^ a b Sweetman (2009), pp. 1132–33.
- ^ Sitar DS (October 1996). "Clinical pharmacokinetics of bambuterol". Clin Pharmacokinet. 31 (4): 246–56. doi:10.2165/00003088-199631040-00002. PMID 8896942.
